Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
New! Collabrity Report (CR) Analytics
Wednesday, November 20, 2024
Lineage’s $66 Million Registered Direct Offering
Forte’s $53 Million Private Placement
Valora’s $30 Million Seed Round
AstraZeneca’s $4 Million Grant
Tuesday, November 19, 2024
C Ray’s $100 Million Series A+
Jupiter’s $70 Million Venture Financing
Qualigen’s $5 Million Private Placement
Monday, November 18, 2024
Avenzo’s $386 Million Series A
Zai’s $230 Million Public Offering
Aclaris’s $80 Million Private Placement
Zenflow’s $24 Million Series C
HCW’s $7 Million Registered Direct Offering and Private Placement
Citius’s $3 Million Registered Direct Offering
Thursday, November 14, 2024
Humacyte’s $15 Million Registered Direct Offering
Calidi’s $8 Million Public Offering
Wednesday, November 13, 2024
Metsera’s $215 Million Series B…More
TRexBio’s $84 Million Series B…More
Virpax’s $5 Million Public Offering
Vivani’s $5 Million Equity Investment
Cyclacel’s $2 Million Warrant Exercise
Tuesday, November 12, 2024
Alentis’s $181 Million Series D
Travere’s $144 Million Public Offering
89bio’s $125 Million Public Offering
Alpha’s $50 Million Public Offering
Vittoria’s $25 Million Private Placement
Monday, November 11, 2024
AbbVie’s $9 Billion Acquisition of Cerevel
Friday, November 8, 2024
Disc Medicine’s $200 Million Debt Financing
AlloVir’s $100 Million Merger with Kalari
ProPhase’s $4 Million Public Offering
Thursday, November 7, 2024
Geron’s $250 Million Royalty and $125 Million Debt Financing
Ocugen’s $30 Million Debt Financing
Wednesday, November 6, 2024
Sonnet’s $50 Million Public Offering
Prognomiq’s $34 Million Series D
Dovetail’s $2 Million Grant
In coordination with an executive placement firm that is independent and unaffiliated with Collabrity, Inc., we may coordinate with executive(s) who are sourced by that firm and also independent and unaffiliated with Collabrity, Inc.: “Collabrity Executive(s)” does not imply an employment or independent contractor relationship with Collabrity, Inc.
Securities offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity Inc. is not a registered broker-dealer, and Finalis Securities LLC and Collabrity Inc. are separate, unaffiliated entities. Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck